Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00699153 · ClinicalTrials.gov registry record · Phase 3
Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery
A Phase 3 study of Ocular Inflammation, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT00699153: Completed Phase 3 study of Ocular Inflammation, sponsored by Bausch & Lomb Incorporated.
NCT00699153 is a Phase 3 study of Ocular Inflammation that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 400 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00699153, a Phase 3 study of Ocular Inflammation, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluation of the clinical safety and efficacy of loteprednol etabonate in an ophthalmic base, when compared to vehicle for the treatment of inflammation following cataract surgery.
Primary Outcome
A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= \>30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.
Conditions Studied
Interventions
- DRUG Loteprednol Etabonate
- DRUG Vehicle of Ophthalmic Loteprednol Etabonate
Study Locations (1)
North Carolina
- Cornerstone Eye Wear - High Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
What the finished NCT00699153 record still lists
NCT00699153 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Ocular Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Loteprednol Etabonate is the first listed.
NCT00699153 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00699153 about?
NCT00699153 is a clinical study titled "Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery". Evaluation of the clinical safety and efficacy of loteprednol etabonate in an ophthalmic base, when compared to vehicle for the treatment of inflammation following cataract surgery.
What is the current status of trial NCT00699153?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2008-06. Estimated completion is 2009-06.
What conditions does trial NCT00699153 study?
This clinical trial studies the following conditions: Ocular Inflammation.
What interventions are being tested in trial NCT00699153?
The interventions under investigation include: Loteprednol Etabonate (DRUG), Vehicle of Ophthalmic Loteprednol Etabonate (DRUG).
Who is sponsoring clinical trial NCT00699153?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00699153 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00699153's enrollment target sits among peer trials
400 922nd of 2000 higher than 1,039 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia